- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.3 2004 Stock Plan, As Amended
- 10.6 Employment Agreement
- 10.17 Manufacturing Services Agreement
- 23.1 Consent of Independent Registered Public Accounting Firm
- 23.2 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification by the Chief Executive Officer Pursuant to Section 240.13A-14
- 31.2 Certification by the Chief Financial Officer Pursuant to Section 240.13A-14
- 32.1 Certification by the Chief Executive Officer Pursuant to 18 U.s.c. 1350
- 32.2 Certification by the Chief Financial Officer Pursuant to 18 U.s.c. 1350
EXHIBIT 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements on Form S-3 (Nos. 333-132330, 333-141964, 333-161236, 333-171628 and 333-179183) and Form S-8 (Nos. 333-137782, 333-144061, 333-160256 and 333-171627) of Chelsea Therapeutics International, Ltd., of our report dated March 10, 2008 on the consolidated statements of operations (not presented separately therein), changes in stockholders’ equity and cash flows (not presented separately therein) for the period from April 3, 2002 (inception) to December 31, 2007. The statement of operations and cash flow information comprise a portion of the cumulative from inception information covering the period from April 3, 2002 (inception) through December 31, 2011 appearing in the Chelsea Therapeutics International, Ltd. Annual Report on Form 10-K for the year ended December 31, 2011.
/s/ J.H. Cohn LLP
Roseland, New Jersey
March 7, 2012